Re: National Kidney Foundation -Abstract: BOM
in response to
by
posted on
Mar 30, 2020 02:46PM
we are missing the change in eGFR within the <60 eGFR cohort of the BETonMACE study. Specifically, the relative change between those receiving standard of care/placebo and those receiving apabetalone. No change??? maybe, but unlikely in my uneducated humble opinion. How else would one explain a 50% RRR of MACE for those receiving apabetalone versus those on standard of care/placebo